Benjamin King
About Benjamin King
Benjamin King is a Scientist specializing in Biomarker and Immunoassay Profiling at Bristol Myers Squibb, with a focus on cancer biology and single cell analysis.
Title
Benjamin King holds the title of Scientist Biomarker and Immunoassay Profiling at Bristol Myers Squibb. He began this role in October 2021, based in Lawrence, New Jersey, United States.
Current Position at Bristol Myers Squibb
Currently, Benjamin King is employed at Bristol Myers Squibb, a leading global biopharmaceutical company. He works as a Scientist Biomarker and Immunoassay Profiling. His focus within the company entails working on biomarkers and immunoassay profiling projects that are crucial for advancing healthcare solutions. His role leverages his extensive expertise in cell, molecular, and biomedical sciences, with a particular emphasis on cancer biology.
Education and Expertise
Benjamin King achieved his Doctor of Philosophy (PhD) in Cell, Molecular, and Biomedical Sciences from the University of Vermont, where he studied from 2010 to 2017. Prior to this, he completed a Bachelor of Arts (BA) in Biology at Middlebury College, attending from 2004 to 2008. King's academic training has equipped him with specialized knowledge in cancer biology, with a specific focus on the heterogeneity among genetically identical individual cells and their implications in complex diseases. He advocates for integrating systems biology and single cell analysis to uncover groundbreaking insights into cancer treatments.
Professional Background at New York University School of Medicine
Benjamin King previously served as a Postdoctoral Fellow at the New York University School of Medicine from 2017 to 2021. During his four-year tenure in the Greater New York City Area, he honed his skills in cancer biology and contributed to significant research initiatives. His work focused on understanding the nuances of cellular behaviors in complex diseases and exploring innovative approaches to treatment.
Research Focus and Interests
Benjamin King has a pronounced interest in how single cell analysis can enhance our understanding and treatment of cancer. His work centers on the biologically significant differences between genetically identical cells and their roles in disease processes. By advocating for the application of systems biology and single cell analysis, he aims to drive revolutionary advancements in oncology. King's commitment to these research methodologies reflects his broader goal of contributing to transformative cancer treatments.